IE
CRNX icon

Israel Englander’s Crinetics Pharmaceuticals CRNX Stock Holding History

Israel Englander’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,400
Closed -$1.66M – 5978
2024
Q1 		$1.66M Buy
+35,400
New +$1.39M ﹤0.01% 3895

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's CRNX Position: Q2 2026 in Review

Israel Englander sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 62,368 shares — an estimated $2.27M sold.

Israel Englander first reported a position in CRNX in Q1 2019 and held it in 22 quarters. The position peaked at $14M in Q4 2025. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Israel Englander reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 62,368 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Israel Englander first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Israel Englander's Crinetics Pharmaceuticals position peaked at $14M in Q4 2025.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.